A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia

Janice P. Dutcher, Deborah Coletti, Elisabeth M. Paietta, Peter H. Wiernik

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.

Original languageEnglish (US)
Pages (from-to)375-380
Number of pages6
JournalLeukemia Research
Volume21
Issue number5
DOIs
StatePublished - May 1997

Fingerprint

Leukemia, Myeloid, Accelerated Phase
Plicamycin
Interferon-alpha
Hydroxyurea
Cytogenetics
Interferons
Drug Therapy
Survival

Keywords

  • Accelerated phase CML
  • Chronic myeloid leukemia (CML)
  • Interferon
  • Leukemia
  • Plicamycin
  • Therapy-CML

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. / Dutcher, Janice P.; Coletti, Deborah; Paietta, Elisabeth M.; Wiernik, Peter H.

In: Leukemia Research, Vol. 21, No. 5, 05.1997, p. 375-380.

Research output: Contribution to journalArticle

Dutcher, Janice P. ; Coletti, Deborah ; Paietta, Elisabeth M. ; Wiernik, Peter H. / A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia. In: Leukemia Research. 1997 ; Vol. 21, No. 5. pp. 375-380.
@article{e2082dfd00bb462eb8f20a273799ae5d,
title = "A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia",
abstract = "Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.",
keywords = "Accelerated phase CML, Chronic myeloid leukemia (CML), Interferon, Leukemia, Plicamycin, Therapy-CML",
author = "Dutcher, {Janice P.} and Deborah Coletti and Paietta, {Elisabeth M.} and Wiernik, {Peter H.}",
year = "1997",
month = "5",
doi = "10.1016/S0145-2126(96)00108-7",
language = "English (US)",
volume = "21",
pages = "375--380",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia

AU - Dutcher, Janice P.

AU - Coletti, Deborah

AU - Paietta, Elisabeth M.

AU - Wiernik, Peter H.

PY - 1997/5

Y1 - 1997/5

N2 - Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.

AB - Thirteen patients with accelerated phase of chronic myeloid leukemia (CML-AC) were treated with intravenous plicamycin and subcutaneous alpha-interferon. Two patients stabilized, three patients had partial hematologic responses and one patient had a hematologic complete response with a major cytogenetic response. Two patients, progressing on hydroxyurea, did not respond, but demonstrated re-sensitization to hydroxyurea after completion of induction therapy and had prolonged return to chronic phase for 30 months and 25 months. Four non-responders subsequently received additional chemotherapy and responded. Median survival of all study patients from the development of accelerated phase of CML was 24 months: substantially longer than other reported series (median 6 months). Plicamycin appears to add efficacy to interferon in the stabilization of accelerated phase of CML.

KW - Accelerated phase CML

KW - Chronic myeloid leukemia (CML)

KW - Interferon

KW - Leukemia

KW - Plicamycin

KW - Therapy-CML

UR - http://www.scopus.com/inward/record.url?scp=0030851551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030851551&partnerID=8YFLogxK

U2 - 10.1016/S0145-2126(96)00108-7

DO - 10.1016/S0145-2126(96)00108-7

M3 - Article

VL - 21

SP - 375

EP - 380

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 5

ER -